Advertisement
Australia markets open in 6 hours 33 minutes
  • ALL ORDS

    8,303.50
    +60.20 (+0.73%)
     
  • AUD/USD

    0.6728
    -0.0007 (-0.11%)
     
  • ASX 200

    8,057.90
    +58.60 (+0.73%)
     
  • OIL

    82.72
    +1.96 (+2.43%)
     
  • GOLD

    2,462.90
    -4.90 (-0.20%)
     
  • Bitcoin AUD

    95,377.89
    -345.98 (-0.36%)
     
  • CMC Crypto 200

    1,329.01
    -13.31 (-0.99%)
     

What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing?

Fulgent Genetics, Inc. (NASDAQ:FLGT), is not the largest company out there, but it saw significant share price movement during recent months on the NASDAQGM, rising to highs of US$23.74 and falling to the lows of US$20.03. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Fulgent Genetics' current trading price of US$20.30 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Fulgent Genetics’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Fulgent Genetics

What Is Fulgent Genetics Worth?

Fulgent Genetics appears to be overvalued by 38% at the moment, based on our discounted cash flow valuation. The stock is currently priced at US$20.30 on the market compared to our intrinsic value of $14.66. This means that the opportunity to buy Fulgent Genetics at a good price has disappeared! But, is there another opportunity to buy low in the future? Given that Fulgent Genetics’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What kind of growth will Fulgent Genetics generate?

earnings-and-revenue-growth
earnings-and-revenue-growth

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Fulgent Genetics' earnings over the next few years are expected to increase by 59%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? FLGT’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe FLGT should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

ADVERTISEMENT

Are you a potential investor? If you’ve been keeping tabs on FLGT for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the optimistic prospect is encouraging for FLGT, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Diving deeper into the forecasts for Fulgent Genetics mentioned earlier will help you understand how analysts view the stock going forward. At Simply Wall St, we have the analysts estimates which you can view by clicking here.

If you are no longer interested in Fulgent Genetics, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.